BHVN ▼ -0.7% - Biohaven Ltd.
$BHVN - Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
28-SEP-2026 07:30 AM ET
Share this post
More filings for $BHVN
View full $BHVN filing history →💬 Comments
Loading comments…
Leave a comment
